CD79B and diffuse large B-cell lymphoma: Polatuzumab vedotin (Pola), an antibody–drug conjugate targeting CD79b, has reshaped frontline therapy for diffuse large B-cell lymphoma (DLBCL) through the landmark POLARIX trial.